Darren McKerrecher

1.6k total citations · 1 hit paper
28 papers, 1.2k citations indexed

About

Darren McKerrecher is a scholar working on Molecular Biology, Organic Chemistry and Surgery. According to data from OpenAlex, Darren McKerrecher has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Organic Chemistry and 8 papers in Surgery. Recurrent topics in Darren McKerrecher's work include Pancreatic function and diabetes (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Synthetic Organic Chemistry Methods (5 papers). Darren McKerrecher is often cited by papers focused on Pancreatic function and diabetes (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Synthetic Organic Chemistry Methods (5 papers). Darren McKerrecher collaborates with scholars based in United Kingdom, United States and Sweden. Darren McKerrecher's co-authors include Richard A. Ward, Nicolas Floc’h, Paul D. Smith, Vikki Flemington, Stephen E. Fawell, Stephen Caddick, F. Geoffrey N. Cloke, David J. D. Wilson, Craig Johnstone and Peter B. Hitchcock and has published in prestigious journals such as Chemical Reviews, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Darren McKerrecher

28 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Challenges and Opportunities in Cancer Drug Resistance

2020 330 citations Richard A. Ward, Nicolas Floc’h et al. profile →

Peers

Countries citing papers authored by Darren McKerrecher

Since Specialization

Citations

This map shows the geographic impact of Darren McKerrecher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren McKerrecher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren McKerrecher more than expected).

Fields of papers citing papers by Darren McKerrecher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darren McKerrecher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren McKerrecher. The network helps show where Darren McKerrecher may publish in the future.

Co-authorship network of co-authors of Darren McKerrecher

This figure shows the co-authorship network connecting the top 25 collaborators of Darren McKerrecher. A scholar is included among the top collaborators of Darren McKerrecher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darren McKerrecher. Darren McKerrecher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR) 2019 ·Cancer Research ·Richard A. Ward, Ambra Bianco, Nicola Colclough, Darren A.E. Cross, (unknown), M. Raymond V. Finlay, Martina Fitzek, Nicolas Floc’h, Sladjana Gagrica, Beverley Hammond, Matthew J. Martin, Darren McKerrecher, Daniel O’Neill, Jonathan P. Orme, Paul D. Smith, Anna D. Staniszewska, Jelena Urosevic, Nicky Whalley, James Yates	1
2	Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation 2019 ·Cancer Research ·Nicolas Floc’h, M. Raymond V. Finlay, Ambra Bianco, (unknown), Nicola Colclough, Darren A.E. Cross, (unknown), Carine Guérot, David Hargreaves, Matthew J. Martin, Darren McKerrecher, Daniel O’Neill, Jonathan P. Orme, Amar Rahi, Paul Smith, Richard A. Ward	9
3	Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions 2018 ·Molecular Cancer Therapeutics ·Nicolas Floc’h, Matthew J. Martin, Jonathan W. Riess, Jonathan P. Orme, Anna D. Staniszewska, Ludovic Ménard, Maria Emanuela Cuomo, Daniel O’Neill, Richard A. Ward, M. Raymond V. Finlay, Darren McKerrecher, Mingshan Cheng, (unknown), Rebekah A. Burich, James Keck, David R. Gandara, Philip C. Mack, Darren A.E. Cross	85
4	Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions. 2017 ·Journal of Clinical Oncology ·Jonathan W. Riess, Nicolas Floc’h, Matthew W. Martin, Jonathon P. Orme, Anna D. Staniszewska, Ludovic Ménard, Maria Emanuela Cuomo, Daniel O’Neill, Richard A. Ward, (unknown), Darren McKerrecher, Mingshan Cheng, (unknown), (unknown), Chunting Ye, James Keck, David R. Gandara, Philip C. Mack, Darren A.E. Cross	5
5	Circumventing Seizure Activity in a Series of G Protein Coupled Receptor 119 (GPR119) Agonists 2014 ·Journal of Medicinal Chemistry ·James S. Scott, (unknown), Katy J. Brocklehurst, Hayley S. Brown, David S. Clarke, Alison Easter, Anne Ertan, Kristin Goldberg, Julian A. Hudson, Stefan Kavanagh, (unknown), Andrew G. Leach, Philip A. MacFaul, Élizabeth Martin, Darren McKerrecher, Paul N. Schofield, Per H. Svensson, (unknown)	16
6	Property-Based Design in the Optimisation of Benzamide Glucokinase Activators 2013 ·Progress in medicinal chemistry ·Darren McKerrecher, Michael J. Waring	4
7	Conformational restriction in a series of GPR119 agonists: Differences in pharmacology between mouse and human 2013 ·Bioorganic & Medicinal Chemistry Letters ·James S. Scott, Katy J. Brocklehurst, Hayley S. Brown, David S. Clarke, Helen Coe, Sam D. Groombridge, (unknown), Philip A. MacFaul, Darren McKerrecher, Paul N. Schofield	14
8	A chemistry wiki to facilitate and enhance compound design in drug discovery 2012 ·Drug Discovery Today ·Graeme R. Robb, Darren McKerrecher, Nicholas J. Newcombe, (unknown)	10
9	Optimisation of aqueous solubility in a series of G protein coupled receptor 119 (GPR119) agonists 2012 ·MedChemComm ·James S. Scott, Alan M. Birch, Katy J. Brocklehurst, Hayley S. Brown, Kristin Goldberg, Sam D. Groombridge, Julian A. Hudson, Andrew G. Leach, Philip A. MacFaul, Darren McKerrecher, (unknown), Paul N. Schofield, Per H. Svensson	12
10	Discovery, optimisation and in vivo evaluation of novel GPR119 agonists 2011 ·Bioorganic & Medicinal Chemistry Letters ·Katy J. Brocklehurst, Anders Broo, Roger J. Butlin, Hayley S. Brown, David S. Clarke, Öjvind Davidsson, Kristin Goldberg, Sam D. Groombridge, (unknown), Andrew G. Leach, Darren McKerrecher, Colm P. O’Donnell, Simon M. Poucher, Paul N. Schofield, James S. Scott, (unknown), (unknown), (unknown)	11
11	Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092 2011 ·MedChemComm ·Michael J. Waring, Craig Johnstone, Darren McKerrecher, Kurt G. Pike, Graeme R. Robb	21
12	Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life 2011 ·Bioorganic & Medicinal Chemistry Letters ·Kurt G. Pike, Joanne V. Allen, Peter W. R. Caulkett, David S. Clarke, Craig S. Donald, (unknown), (unknown), Craig Johnstone, Darren McKerrecher, (unknown), (unknown), (unknown)	26
13	Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators 2011 ·MedChemComm ·Michael J. Waring, Iain J. Brogan, Matthew P. Coghlan, Craig Johnstone, Huw B. Jones, Brendan Leighton, Darren McKerrecher, Kurt G. Pike, Graeme R. Robb	16
14	Dissociated non-steroidal glucocorticoid receptor modulators: an update on new compounds 2008 ·Expert Opinion on Therapeutic Patents ·Heike Schäcke, Markus Berger, T. Hansson, Darren McKerrecher, Hartmut Rehwinkel	34
15	Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats 2006 ·British Journal of Pharmacology ·(unknown), (unknown), (unknown), Darren McKerrecher, Craig Johnstone, Kurt G. Pike, Petter Holme, (unknown), Débora Gil, Matthew P. Coghlan, Brendan Leighton	67
16	Design of a potent, soluble glucokinase activator with excellent in vivo efficacy 2006 ·Bioorganic & Medicinal Chemistry Letters ·Darren McKerrecher, Joanne V. Allen, Peter W. R. Caulkett, Craig S. Donald, (unknown), (unknown), (unknown), Craig Johnstone, Clifford D. Jones, Kurt G. Pike, (unknown), (unknown)	71
17	Discovery, synthesis and biological evaluation of novel glucokinase activators 2005 ·Bioorganic & Medicinal Chemistry Letters ·Darren McKerrecher, Joanne V. Allen, (unknown), Scott Boyd, Peter W. R. Caulkett, Gordon S. Currie, (unknown), (unknown), (unknown), (unknown), (unknown), Barry R. Hayter, Roger F.L. James, (unknown), Craig Johnstone, Clifford D. Jones, (unknown), (unknown), (unknown)	48
18	The First Example of Simple Oxidative Addition of an Aryl Chloride to a Discrete Palladium N-Heterocyclic Carbene Amination Precatalyst 2002 ·Organometallics ·Stephen Caddick, F. Geoffrey N. Cloke, Peter B. Hitchcock, John Leonard, Alexandra K. de K. Lewis, Darren McKerrecher, (unknown)	82
19	Sonogashira coupling reactions of highly oxygenated vinyl halides: The first synthesis of harveynone and epi-harveynone 1996 ·Tetrahedron Letters ·Andrew E. Graham, Darren McKerrecher, D. Huw Davies, Richard J. K. Taylor	51
20	The preparation of 4‐substituted pyrylium salts and their use in dienal synthesis 1996 ·Journal of Heterocyclic Chemistry ·Patchanee Charoenying, K. Hemming, Darren McKerrecher, Richard J. K. Taylor	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact